Compare ONCY & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONCY | TNXP |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.5M | 81.3M |
| IPO Year | 2002 | 2008 |
| Metric | ONCY | TNXP |
|---|---|---|
| Price | $0.38 | $2.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $4.42 | ★ $34.00 |
| AVG Volume (30 Days) | 953.1K | ★ 1.0M |
| Earning Date | 11-24-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $333.23 |
| Revenue Next Year | N/A | $99.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $0.37 | $3.21 |
| 52 Week High | $1.30 | $20.56 |
| Indicator | ONCY | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 32.34 | 11.64 |
| Support Level | N/A | N/A |
| Resistance Level | $0.46 | $12.99 |
| Average True Range (ATR) | 0.04 | 0.41 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 25.50 | 2.49 |
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.